Tower Research Capital (TRC)’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Tower Research Capital (TRC)’s Portfolio IMNP Stock Details IMNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3	Closed	–	–	5344
2016 Q1	$0	Hold	3	–	–	﹤0.01%	5417
2015 Q4	$0	Buy	+3	New	+$63	﹤0.01%	5431
2014 Q4	–	Sell	-44	Closed	-$3K	–	5094
2014 Q3	$3K	Buy	+44	New	+$3.13K	﹤0.01%	3681

Other funds holding IMNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EEG

E.E. Geduld $178M AUM 29.34% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

IFS

Ifrah Financial Services Little Rock, Arkansas $409M AUM 28.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tower Research Capital (TRC)'s IMNP Position: Q2 2016 in Review

Tower Research Capital (TRC) sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2016, closing a stake of 3 shares.

Tower Research Capital (TRC) first reported a position in IMNP in Q3 2014 and held it in 3 quarters. The position peaked at $3K in Q3 2014. 11 funds tracked by Wall St. Rank hold IMNP as of Q2 2016.

Tower Research Capital (TRC) reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
Tower Research Capital (TRC) sold 3 Immune Pharmaceuticals Inc. shares in Q2 2016.
Tower Research Capital (TRC) first reported a position in Immune Pharmaceuticals Inc. in Q3 2014 and held it in 3 quarters.
Tower Research Capital (TRC)'s Immune Pharmaceuticals Inc. position peaked at $3K in Q3 2014.
11 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2016, filed 10 Aug 2016.